Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)

NCT03955471 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03955471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03955471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Lead sponsor
Tesaro, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 3, 2019
Completion date
January 12, 2022
Enrollment
41 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms